Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2. (Q36826045)

From Wikidata

Jump to navigation Jump to search

scientific article published on March 2002

edit

Language	Label	Description	Also known as
English	Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2.	scientific article published on March 2002

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PMC publication ID

2505181

retrieved

16 August 2017

title

Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2. (English)

1 reference

stated in

Europe PubMed Central

PMC publication ID

2505181

retrieved

16 August 2017

main subject

metastatic melanoma

1 reference

based on heuristic

inferred from title

author name string

David M Weinreich

series ordinal

1

1 reference

stated in

Europe PubMed Central

PMC publication ID

2505181

retrieved

16 August 2017

Steven A Rosenberg

series ordinal

2

1 reference

stated in

Europe PubMed Central

PMC publication ID

2505181

retrieved

16 August 2017

language of work or name

English

1 reference

based on heuristic

inferred from title

publication date

1 March 2002

1 reference

stated in

Europe PubMed Central

PMC publication ID

2505181

retrieved

16 August 2017

published in

Journal of Immunotherapy

1 reference

stated in

Europe PubMed Central

PMC publication ID

2505181

retrieved

16 August 2017

volume

25

1 reference

stated in

Europe PubMed Central

PMC publication ID

2505181

retrieved

16 August 2017

issue

2

1 reference

stated in

Europe PubMed Central

PMC publication ID

2505181

retrieved

16 August 2017

page(s)

185-187

1 reference

stated in

Europe PubMed Central

PMC publication ID

2505181

retrieved

16 August 2017

cites work

Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2505181

retrieved

29 September 2017

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2505181

retrieved

29 September 2017

Duration of survival for disseminated malignant melanoma: results of a meta-analysis.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2505181

retrieved

29 September 2017

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2505181

retrieved

29 September 2017

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2505181

retrieved

29 September 2017

Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2505181

retrieved

29 September 2017

Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2505181

retrieved

5 September 2018

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2505181

retrieved

20 October 2018

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/12074048

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1097/00002371-200203000-00006

1 reference

stated in

Europe PubMed Central

PMC publication ID

2505181

retrieved

16 August 2017

PMC publication ID

2505181

1 reference

stated in

Europe PubMed Central

PMC publication ID

2505181

retrieved

16 August 2017

PubMed publication ID

12074048

1 reference

stated in

Europe PubMed Central

PMC publication ID

2505181

retrieved

16 August 2017

ResearchGate publication ID

11300913

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36826045&oldid=1627262589"